Risultati per: Linee guida ESC 2023 sull’endocardite

We sincerely thank the 646 peer reviewers who completed manuscript reviews for JAMA Internal Medicine in 2023.

JAMA Psychiatry saw a post–COVID-19 pandemic period of steady growth and impact in 2023. Our editorial team worked hard to maintain high standards, stay abreast of developments in the field, and present to our audience the best psychiatric research of the year. Among many others, we published a randomized clinical trial on sequential adaptive interventions for psychosis risk, an article on the adverse impact of abortion restrictions on mental health, and a Viewpoint series on mental health in a changing planet. We also continued to cover all aspects of the therapeutic potential and pitfalls of psychedelics and even devoted one of our popular podcasts to the topic.

We live in a tumultuous time of increased health care challenges within a milieu of ongoing COVID-19, climate change, war, gun violence, racial and ethnic discrimination, political divisions, and ongoing financial challenges to health care systems and financing. Amidst this background, the JAMA Internal Medicine editors came together to renew our commitment to publishing evidence to inform and improve health and health care. Our commitment is captured in our new mission statement: “To advance the equitable, person-centered, and evidence-based practice of internal medicine through publication of scientifically rigorous, innovative, and inclusive research, review, and commentary that informs dialogue and action with clinical, public health, and policy impact.”

We sincerely thank the 659 peer reviewers who completed manuscript reviews for JAMA Psychiatry in 2023.

2023 Has been a busy year for JAMA Oncology and its editors. We have had the pleasure of receiving a substantial number of submissions and reviewing an exciting array of scientific studies, opinions, and reviews. The use of artificial intelligence to bolster the oncology workforce was one of our most popular topics, but the verdict is still out on whether a chatbot can ace the medical, surgical, or radiation oncology board examinations. We continued to learn more this year about the role of physical activity in preventing cancer recurrence and even in preventing multiple different types of cancer. Although several studies have evaluated different intensities of activity, we still do not have an exact number to write on a physical activity prescription for each patient. We just know that we should probably give a physical activity prescription to each patient. We have reported results from several large phase 3 randomized clinical trials affecting standard of care, as well as exciting and promising results from smaller phase 1 and 2 studies with outstanding correlative science. And JAMA Oncology continues to publish important studies reporting the global health impact of cancer. We hope that you enjoyed reading these articles as much as we enjoyed choosing them for publication.

2023 Was another exceptional year for JAMA Dermatology. The editorial team evaluated a steady number of article submissions (Table). A total of 956 of 2756 submissions were research articles. Acceptance rates remained stable, with 10% of submissions overall and 11% of research articles accepted for publication. The journal continued to maintain its goal of reducing the time to publication, keeping the median days of acceptance to publication to 63 days while offering timely editorial decisions, including maintaining the median time to first decision without peer review to 4 days. The median time of receipt to first decision with peer review increased slightly to 63 days, highlighting an area for process improvement aligned with our commitment to publishing excellence. JAMA Dermatology’s Journal Impact Factor remained high at 10.9.

1,8 milioni di bambini non vaccinati negli ultimi tre anni

Agenas, +6% sul 2022. Il 68% Codici bianchi e verdi

Annals of Internal Medicine, Ahead of Print.